Skip to main
DBVT

DBVT Stock Forecast & Price Target

DBVT Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 17%

Bulls say

DBV Technologies SA is positioned favorably due to the successful Phase 3 VITESSE trial, which met its primary endpoint, significantly enhancing confidence in the Viaskin Peanut program for peanut-allergic children aged 4-7. Continued treatment has shown efficacy improvements and reduced reaction severity over time, which suggests a compelling long-term benefit profile beyond initial treatment phases. With expectations for a Biologics License Application (BLA) submission in the first half of 2026 and an increased probability of success for the Viaskin platform, the outlook for DBV Technologies remains positive.

Bears say

DBV Technologies SA experienced a significant financial setback in FY25, reporting a net loss of approximately $147 million, equating to a loss of $1.05 per share. Key risks impacting the company's outlook include potential failures in clinical studies, challenges in securing regulatory approval, and a smaller-than-expected commercial opportunity due to market size, competition, and pricing dynamics. Furthermore, without evidence of clinical significance and safety, as well as potential reimbursement issues, DBV Technologies may struggle to generate revenue and see limited product adoption, thereby dampening its overall market potential.

DBVT has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 17% predict a Strong Sell.

This aggregate rating is based on analysts' research of DBV Technologies SA Sponsored ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DBV Technologies SA Sponsored ADR (DBVT) Forecast

Analysts have given DBVT a Buy based on their latest research and market trends.

According to 6 analysts, DBVT has a Buy consensus rating as of Apr 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DBV Technologies SA Sponsored ADR (DBVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.